PFIZER'S PHASE 3 TRIAL OF SIGVOTATUG VEDOTIN IN PREVIOUSLY TREATED METASTATIC NSCLC MISSED ITS OVERALL SURVIVAL GOAL VERSUS DOCETAXEL, THOUGH THE DRUG MAINTAINED A MANAGEABLE SAFETY PROFILE AND SHOWED STRONGER BENEFIT TRENDS IN SECOND-LINE PATIENTS.
